Survival and Perioperative Outcomes After Addition of Immunotherapy to Neoadjuvant Chemoradiotherapy for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma
Thoracic Cancer · 2025
DOI: 10.1111/1759-7714.70054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Canjun Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sci…. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy, Esophageal Neoplasms, Immunotherapy. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Currently, neoadjuvant chemoradiotherapy combined with immunotherapy (NCRI) for patients with locally advanced esophageal squamous cell carcinoma (ESCC) is attracting attention. The purpose of this study was to compare the surgical outcomes and survival between patients receiving NCRI and neoadjuvant chemoradiotherapy (NCRT) followed by surgery.
Methods
This study retrospectively included patients with locally advanced ESCC and treated with NCRI or NCRT followed by esophagectomy. Two groups were compared for pathologic complete response (pCR) rate, R0 resection rate, and 3‐year recurrence‐free survival (RFS). Surgery time, the number of lymph nodes removed, postoperative complications, and 30‐day mortality were also compared. Propensity score matching (PSM) was performed to minimize the potential impact of confounding factors.
Results
After PSM, patients in the NCRI group showed a significantly higher pCR rate compared with those in the NCRT group (54.2% vs. 27.1%, p = 0.046). R0 resection rate (100% vs. 89.6%, p = 0.251), surgery time ( p = 0.614), the number of lymph nodes removed ( p = 0.526), the incidence of total postoperative complications (46.4% vs. 37.9%, p = 0.564) and 30‐day mortality (3.6% vs. 1.1%, p = 0.983) were comparable between the two groups. The NCRI group exhibited a significantly higher 3‐year RFS rate compared to the NCRT group (79.2% vs. 62.5%, p = 0.032).
Conclusion
For patients with locally advanced ESCC, NCRI showed a significantly higher pCR rate than conventional NCRT, without increased operative risk. NCRI followed by surgery exhibited a superior RFS compared to NCRT followed by surgery. Prospective studies are needed in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID-Profile: Canjun Li, Lei Deng, Tao Zhang, Zongmei Zhou, Yin Li
Zitieren
APA
Li, C., Wang, X., Deng, L., Wang, J., Zhang, T., Wang, W., Liu, W., Lv, J., Feng, Q., Zhou, Z., Chen, X., Zhang, R., Qin, J., Li, Y., & Bi, N. (2025). Survival and Perioperative Outcomes After Addition of Immunotherapy to Neoadjuvant Chemoradiotherapy for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70054
Vancouver
Li C, Wang X, Deng L, Wang J, Zhang T, Wang W, et al. Survival and Perioperative Outcomes After Addition of Immunotherapy to Neoadjuvant Chemoradiotherapy for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70054
BibTeX
@article{Li2025,
author = {Li, Canjun and Wang, Xin and Deng, Lei and Wang, Jianyang and Zhang, Tao and Wang, Wenqing and Liu, Wenyang and Lv, Jima and Feng, Qinfu and Zhou, Zongmei and Chen, Xiankai and Zhang, Ruixiang and Qin, Jianjun and Li, Yin and Bi, Nan},
title = {Survival and Perioperative Outcomes After Addition of Immunotherapy to Neoadjuvant Chemoradiotherapy for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma},
journal = {Thoracic Cancer},
year = {2025},
doi = {10.1111/1759-7714.70054}
}
EUVIMED